Selective blood sampling for FGF-23 in tumor-induced osteomalacia

Tumor-induced osteomalacia (TIO) is caused by the hormone fibroblast growth factor 23 (FGF-23). It is mainly produced in the tissue of mesenchymal tumors. Patients with TIO frequently suffer from a chronic decompensated pain syndrome and/or muscle weakness with postural deformity. Despite the sever...

Full description

Bibliographic Details
Main Authors:	Hans-Christof Schober, Christian Kneitz, Franziska Fieber, Kathrin Hesse, Henry Schroeder
Format:	Article
Language:	English
Published:	Bioscientifica 2017-10-01
Series:	Endocrinology, Diabetes & Metabolism Case Reports
Online Access:	https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-17-0006

id	doaj-f109abc023e74e88aa0bce70c1f37aef
record_format	Article
spelling	doaj-f109abc023e74e88aa0bce70c1f37aef2020-11-24T21:40:10ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732052-05732017-10-01111510.1530/EDM-17-0006Selective blood sampling for FGF-23 in tumor-induced osteomalaciaHans-Christof Schober0Christian Kneitz1Franziska Fieber2Kathrin Hesse3Henry Schroeder4Department of Internal Medicine, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, Germany;Department of Endocrinology, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, GermanyDepartment of Endocrinology, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, GermanyDepartment of Endocrinology, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, GermanyDepartment of Internal Medicine, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, Germany;Department of Endocrinology, Rheumatology/Immunology, Klinikum Südstadt Rostock, Rostock, GermanyDepartment of Neurosurgery, Universitätsmedizin Greifswald, Greifswald, GermanyTumor-induced osteomalacia (TIO) is caused by the hormone fibroblast growth factor 23 (FGF-23). It is mainly produced in the tissue of mesenchymal tumors. Patients with TIO frequently suffer from a chronic decompensated pain syndrome and/or muscle weakness with postural deformity. Despite the severity of the disease, the diagnosis is frequently established late. In some cases, it takes several years to establish the condition. This case report concerning a 68-year old woman demonstrates the selective blood sampling for FGF-23 as path-breaking diagnostics to confirm the diagnosis of a neuroendocrine tumor.https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-17-0006
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hans-Christof Schober Christian Kneitz Franziska Fieber Kathrin Hesse Henry Schroeder
spellingShingle	Hans-Christof Schober Christian Kneitz Franziska Fieber Kathrin Hesse Henry Schroeder Selective blood sampling for FGF-23 in tumor-induced osteomalacia Endocrinology, Diabetes & Metabolism Case Reports
author_facet	Hans-Christof Schober Christian Kneitz Franziska Fieber Kathrin Hesse Henry Schroeder
author_sort	Hans-Christof Schober
title	Selective blood sampling for FGF-23 in tumor-induced osteomalacia
title_short	Selective blood sampling for FGF-23 in tumor-induced osteomalacia
title_full	Selective blood sampling for FGF-23 in tumor-induced osteomalacia
title_fullStr	Selective blood sampling for FGF-23 in tumor-induced osteomalacia
title_full_unstemmed	Selective blood sampling for FGF-23 in tumor-induced osteomalacia
title_sort	selective blood sampling for fgf-23 in tumor-induced osteomalacia
publisher	Bioscientifica
series	Endocrinology, Diabetes & Metabolism Case Reports
issn	2052-0573 2052-0573
publishDate	2017-10-01
description	Tumor-induced osteomalacia (TIO) is caused by the hormone fibroblast growth factor 23 (FGF-23). It is mainly produced in the tissue of mesenchymal tumors. Patients with TIO frequently suffer from a chronic decompensated pain syndrome and/or muscle weakness with postural deformity. Despite the severity of the disease, the diagnosis is frequently established late. In some cases, it takes several years to establish the condition. This case report concerning a 68-year old woman demonstrates the selective blood sampling for FGF-23 as path-breaking diagnostics to confirm the diagnosis of a neuroendocrine tumor.
url	https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-17-0006
work_keys_str_mv	AT hanschristofschober selectivebloodsamplingforfgf23intumorinducedosteomalacia AT christiankneitz selectivebloodsamplingforfgf23intumorinducedosteomalacia AT franziskafieber selectivebloodsamplingforfgf23intumorinducedosteomalacia AT kathrinhesse selectivebloodsamplingforfgf23intumorinducedosteomalacia AT henryschroeder selectivebloodsamplingforfgf23intumorinducedosteomalacia
_version_	1725927756490866688

Selective blood sampling for FGF-23 in tumor-induced osteomalacia

Similar Items